Prostate Cancer

Itraconazole has one of its clearest early clinical signals in metastatic castration-resistant prostate cancer.

Overview

This is one of the most important clinical pages in the itraconazole topic because it includes prospective phase II data rather than preclinical logic alone.

Key human data

• A phase II study using 600 mg daily reported a PSA progression-free survival rate of 48% at 24 weeks in men with metastatic castration-resistant prostate cancer

• This is one of the stronger early clinical indications that itraconazole may have real biological activity in an oncology setting

Practical interpretation

The prostate cancer page is central to the itraconazole repurposing story because it moves beyond theory and into measurable human clinical signal.

References

Repurposing itraconazole as an anticancer agent
https://pmc.ncbi.nlm.nih.gov/articles/PMC5536437/